920 related articles for article (PubMed ID: 19725474)
21. The view from two sides: a qualitative study of community and medical perspectives on screening for colorectal cancer using FOBT.
Clavarino AM; Janda M; Hughes KL; Del Mar C; Tong S; Stanton WR; Aitken JF; Leggett BA; Newman B
Prev Med; 2004 Sep; 39(3):482-90. PubMed ID: 15313087
[TBL] [Abstract][Full Text] [Related]
22. Better acceptance of Fecal Occult Blood Test (FOBT) for colorectal cancer screening during hospitalization.
Keller R; Schätzle A; Flieger D; Christl SU; Fischbach W
Z Gastroenterol; 2003 Jul; 41(7):655-8. PubMed ID: 12858236
[TBL] [Abstract][Full Text] [Related]
23. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
[TBL] [Abstract][Full Text] [Related]
24. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
[TBL] [Abstract][Full Text] [Related]
25. Is PillCam COLON capsule endoscopy ready for colorectal cancer screening? A prospective feasibility study in a community gastroenterology practice.
Sieg A; Friedrich K; Sieg U
Am J Gastroenterol; 2009 Apr; 104(4):848-54. PubMed ID: 19240710
[TBL] [Abstract][Full Text] [Related]
26. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
27. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
Malila N; Oivanen T; Hakama M
Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
[TBL] [Abstract][Full Text] [Related]
28. Screening for colorectal cancer.
Saliangas K
Tech Coloproctol; 2004 Nov; 8 Suppl 1():s10-3. PubMed ID: 15655587
[TBL] [Abstract][Full Text] [Related]
29. Colorectal cancer mass screening event utilising quantitative faecal occult blood test.
Chew MH; Suzanah N; Ho KS; Lim JF; Ooi BS; Tang CL; Eu KW
Singapore Med J; 2009 Apr; 50(4):348-53. PubMed ID: 19421676
[TBL] [Abstract][Full Text] [Related]
30. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
[TBL] [Abstract][Full Text] [Related]
31. Colorectal cancer test use--Maryland, 2002-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
[TBL] [Abstract][Full Text] [Related]
32. Screen compliance rates in 14-years annual screening program for colorectal cancer with immunochemical fecal occult blood test-- identification of higher priority subjects in health education.
Wei N; Nakama H; Li T
Eur J Med Res; 1998 Jul; 3(7):341-4. PubMed ID: 9682030
[TBL] [Abstract][Full Text] [Related]
33. Survival of patients diagnosed with colorectal cancer through a television-advertised screening program.
Slusser SO; Liberski SM; McGarrity TJ
Am J Gastroenterol; 1996 Aug; 91(8):1563-6. PubMed ID: 8759662
[TBL] [Abstract][Full Text] [Related]
34. A 25-year follow-up of a population screened with faecal occult blood test in Finland.
Malila N; Hakama M; Pukkala E
Acta Oncol; 2007; 46(8):1103-6. PubMed ID: 17851857
[TBL] [Abstract][Full Text] [Related]
35. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer (Br J Surg 2009; 96: 533-540).
Nash GF
Br J Surg; 2009 Aug; 96(8):956-7; author reply 957. PubMed ID: 19591144
[No Abstract] [Full Text] [Related]
36. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008.
Choi KS; Lee HY; Jun JK; Shin A; Park EC
J Gastroenterol Hepatol; 2012 Jun; 27(6):1070-7. PubMed ID: 22004224
[TBL] [Abstract][Full Text] [Related]
37. The feasibility of FOBT tests in colorectal cancer screening in Dobrogea.
Suceveanu AI; Suceveanu A; Dumitru E; Alexandrescu L; Voinea F
Rom J Gastroenterol; 2005 Sep; 14(3):213-7. PubMed ID: 16200229
[TBL] [Abstract][Full Text] [Related]
38. Detecting colorectal cancer with a large scale fecal occult blood testing program.
Gregorio DI; Lolachi P; Hansen H
Public Health Rep; 1992; 107(3):331-5. PubMed ID: 1594743
[TBL] [Abstract][Full Text] [Related]
39. Getting adequate information across to colorectal cancer screening subjects can be difficult.
van Rijn AF; van Rossum LG; Deutekom M; Laheij RJ; Bossuyt PM; Fockens P; Dekker E; Jansen JB
J Med Screen; 2008; 15(3):149-52. PubMed ID: 18927098
[TBL] [Abstract][Full Text] [Related]
40. Are there gender differences in colorectal cancer test use prevalence and correlates?
McQueen A; Vernon SW; Meissner HI; Klabunde CN; Rakowski W
Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):782-91. PubMed ID: 16614124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
